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Ryan C Smith1,3, Daisy D Colón-López2,3 and Jürgen Bosch2,3*Abstract
Background: Subtilisin-like protease 2 (SUB2) is a conserved serine protease utilized by Plasmodium parasites as a
surface sheddase required for successful merozoite invasion of host red blood cells and has been implicated in
ookinete invasion of the mosquito midgut. To determine if SUB2 is a suitable vaccine target to interfere with
malaria parasite development, the effects of SUB2-immunization on the Plasmodium life cycle were examined in
its vertebrate and invertebrate hosts.
Methods: Swiss Webster mice were immunized with SUB2 peptides conjugated to Keyhole limpet hemocyanin
(KLH) or KLH alone, and then challenged with Plasmodium berghei. To determine the effects of immunization on
parasite development, infected mice were evaluated by blood film and Giemsa staining. In addition, collected
immune sera were used to perform passive immunization experiments in non-immunized, P. berghei-infected mice
to determine the potential role of SUB2 in parasite development in the mosquito.
Results: Following P. berghei challenge, SUB2-immunized mice develop a lower parasitaemia and show improved
survival when compared to control immunized mice. Moreover, SUB2 immunization results in an increase in the
number of multiply invaded red blood cells, suggesting that SUB2 antibodies interfere with merozoite invasion.
Passive immunization experiments imply that SUB2 may not have a major role in ookinete invasion, but this requires
further investigation.
Conclusion: By interfering with red blood cell invasion, immunization against SUB2 limits malaria parasite development
and confers protection from severe malaria. Together, these results provide proof-of-principle evidence for
future investigation into the use of SUB2 as a vaccine or drug target to interrupt parasite development in more
relevant human malaria models.
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Obligate intracellular parasites from the genus Plasmo-
dium are the agents responsible for malaria, placing an
estimated 3.4 billion people at risk of the disease
throughout the world [1]. Five species of Plasmodium
parasites cause human malaria, yet the largest impacts
to public health are primarily caused by Plasmodium
falciparum in sub-Saharan Africa [2].* Correspondence: jbosch@jhu.edu
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unless otherwise stated.Malaria parasites undergo a complex life cycle in their
mosquito and human hosts, which require Plasmodium
parasites to invade and replicate in multiple cell types
and host environments. To accomplish these develop-
mental progressions, Plasmodium parasites utilize spe-
cific invasion ligands and proteases to facilitate host cell
invasion [3,4]. Merozoite invasion of red blood cells
(RBCs) has been studied in the most detail and involves
a large repertoire of surface proteins that contribute to
multiple invasion pathways [3]. Similarly, recent evi-
dence suggests that ookinete invasion of the mosquito
midgut may also involve multiple surface proteins and
invasion pathways [5]. While both merozoite invasion oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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these stages have attracted recent attention as targets for a
blood stage [6-8] or transmission-blocking vaccines [9-11].
As a shared component of merozoite and ookinete
invasion pathways, subtilisin-like protease 2 (SUB2) is an
ideal candidate to interfere with the disease-causing forms
of malaria asexual development, as well as development in
the obligate mosquito host. In merozoites, SUB2 accumu-
lates in the parasite micronemes and is secreted onto the
merozoite surface upon schizont rupture [12]. There, it is
believed that SUB2 interacts with an actin-dependent
motor to behave as a sheddase, cleaving surface-bound
MSP1 and AMA1 on the parasite membrane [12,13]. As
SUB2 moves to the posterior end of the merozoite during
RBC invasion, these substrates are cleaved at a certain dis-
tance relative to the membrane with minimal sequence spe-
cificity, in contrast to other proteases [12]. While little is
known regarding SUB2 function during ookinete invasion,
limited evidence would suggest that it is secreted by ooki-
netes during mosquito midgut invasion [14]. In cells that
have undergone ookinete invasion, SUB2 is found in pro-
tein aggregates in close association with the actin cytoskel-
eton and may function to disrupt the host cytoskeletal
network to facilitate invasion [14]. While evidence would
suggest that SUB2 is an integral component of Plasmodium
parasite development due to its crucial role in RBC inva-
sion [12,15], attempts to further define its role in the sexual
stages of parasite development have yet to be explored.
Although these invasive stages are transient, both stages
likely require SUB2 activity for the processing and shedding
of parasite surface ligands. Despite the short window of op-
portunity to target these stages, naturally acquired immun-
ity predominantly targets proteins involved in merozoite
invasion [7,8]. Included among several merozoite surface
antigens or proteins secreted during merozoite invasion,
SUB2 was determined to be a strong target candidate to
elicit malaria protective immunity [7].
To determine if SUB2 is a viable malaria vaccine candi-
date targeting both the asexual and sexual life cycles of
Plasmodium, two synthetic peptides were designed repre-
senting solvent exposed regions of the Plasmodium berghei
SUB2 catalytic domain to evaluate the effects of SUB2
immunization in mice. In the present study immunization
with peptides directed at P. berghei SUB2 confers protective
immunity in mice from developing severe malaria infection
by attenuating parasite growth via promoting aberrant mer-
ozoite invasion. These results therefore validate SUB2 as a
novel target against malaria infection in a mouse model
system.
Methods
SUB2 homology modeling and visualization
Homology model of P. berghei SUB2 (PlasmoDB code:
PBANKA_091170, Gene ID: 3423789) was generatedusing the I-TASSER protein structure and function pre-
diction server using default settings [16]. From all the
models predicted by the server, the one with the highest
confidence score was used for further modeling. Models
were visualized using PyMol (PyMoL Molecular Graphics
System, Version 1.6.0.0 Schrödinger, LLC).
Mice
Female Swiss Webster mice (~21-24 g) were purchased
from Harlan and maintained in accordance with the rec-
ommendations of the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
All animal procedures were approved by the Institutional
Animal Care and Use Committee of the Johns Hopkins
University (Protocol number MO09H58).
SUB2 immunization
Synthetic SUB2 peptides conjugated to keyhole limpet
haemocyanin (KLH) through the cysteine at the N-
(Sub2 Peptide #2- CRTSIKIVSKDKKTI) or C-terminus
(Sub2 Peptide #1- KYSDRYEMTDELFDC) via a –SH bond
were produced by GenScript Corporation (Piscataway,
NJ, USA).
Female Swiss Webster mice (~21-24 g) were primed
with a 50:50 mixture (50 μg/mouse) of both SUB2 peptides
in phosphate-buffered saline (PBS) or 50 μg of a control
KLH carrier in PBS with either complete Freund’s adjuvant
(CFA) or incomplete Freund’s adjuvant (IFA) in a 1:1 emul-
sion and immunized by intraperitoneal injection (ip). Mice
were boosted four times in two week intervals with 50 μg/
mouse of peptide in a 1:1 emulsion with IFA via ip injec-
tion. Serum was collected from each individual mouse prior
to priming, as well as the third and fourth boosting immu-
nizations to monitor antibody titres. Two weeks after the
final boosting immunization, animals were used for subse-
quent challenge experiments with P. berghei parasites.
Plasmodium berghei and Plasmodium falciparum RNA
isolation and cDNA production
Plasmodium berghei strain ANKA 2.34 total RNA was
prepared from blood of an infected Swiss Webster
mouse (~10% parasitaemia) obtained via cardiac punc-
ture and isolated using TRIzol Reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s specifica-
tions. Two μg of total RNA was used as a template for
the production of cDNA using SuperScriptIII (Invitrogen,
Carlsbad, CA).
Approximately 1 μg of total RNA from asynchronized
P. falciparum strain 3D7 parasites was isolated using TRI
Reagent (Molecular Research Center, Inc, Cincinnati, OH)
and treated with DNase I (New England Biolabs, Ipswich,
MA) according to the manufacturer’s protocol. Synthesis of
complementary DNA was performed with the SuperScript
First-Strand Synthesis System for RT-PCR (Invitrogen).
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Plasmodium berghei SUB2 N476 - N1185 (PlasmoDB code:
PBANKA_091170, Gene ID: 3423789) and P. falciparum
SUB2 N528 - S1135 (PlasmoDB code: PF3D7_1136900,
Gene ID: 810927) coding sequences were amplified
using cDNA obtained from P. berghei ANKA 2.34 or
P. falciparum 3D7 strains using the respective primers
PbSUB2_Fwd: 5′ CTCCATGGCGAATAATTCAAATG
CATTTTTGAGTGTAGAC 3′, PbSUB2_Rev: 5′ ACG
GATCCGTTATCATGCTCATATAAATTATATAAAGC
3′, PfSUB2_Fwd: 5′ ATCCATGGCGAATAATAAAAA
AATTTTGTTAAATGTTGAT 3′ and PfSUB2_Rev: 5′
ACGGATCCACTATCATATTCATACAAATTATATAA
GGC 3′. PCR products were amplified using Phusion®
High-Fidelity DNA polymerase (New England Biolabs)
with an annealing temperature gradient of 52-70°C for
30 sec, followed by extension at 72°C for 2 min.
SUB2 PCR products were inserted in frame using NcoI
and BamHI restriction sites into a modified pRSF-1b
vector (EMD Millipore, Billerica, MA) for expression as
a maltose binding protein (MBP)-fusion protein with a
C-terminal 6×His tag for purification and detection
purposes as previously described [17]. Positive clones
were screened using colony PCR with primers de-
scribed above and insertion sequences were confirmed
by sequencing.Recombinant protein expression and purification
MBP-SUB2 fusion constructs were transformed into
Rosetta 2 (DE3) competent Escherichia coli (Novagen)
for protein expression. Cells were grown in the presence
of 1.5% glucose and 50 μg/ml kanamycin in 500 ml 1X
Terrific Broth media until OD600 of ~3.0 and induced
with a final concentration of 0.5 mM IPTG. Recombinant
proteins were expressed overnight at 20°C under vigorous
shaking at 250 rpm.
Bacteria were harvested by centrifugation at 2,500 rpm
for 30 min at 4°C. Bacterial pellets were resuspended in
lysis buffer (25 mM Tris pH 9.0, 100 mM NaCl) and
lysis was performed using an Emulsiflex C5 cells dis-
ruptor (Avestin Inc., Ottawa, Canada) at 100 MPa.
Whole cell lysates were fractionated by centrifugation at
17,000 rpm for 1 hr at 4°C and the supernatant was ap-
plied to an open gravity column (BioRad) containing
1 ml of amylose resin (New England Biolabs) for affinity
capture of the MBP-tagged fusion protein. Bound pro-
tein was washed with lysis buffer and eluted in the
presence of 20 mM maltose. Elution samples from the
amylose resin purification steps were applied to an
affinity column containing Cobalt-Talon resin (Clontech,
Mountain View, CA) for secondary purification with the
6×His tag. Bound protein was washed with lysis buffer
and eluted with 200 mM imidazole. Elution sampleswere concentrated using Nanosep Centrifugal Devices
(Sigma-Aldrich, St. Louis, MO) with a 10 kDa cut-off.
Western blots
Approximately 1.7 μg of recombinant PbSUB2 and PfSUB2,
and ~3 μg MBP (fusion protein only) were separated on a
12% SDS-PAGE gel. Following electrophoresis, the gel was
washed in diH20 for 10 min and equilibrated in 1X transfer
buffer (25 mM Tris, 192 mM glycine, 20% methanol,
0.0375% SDS). Proteins were transferred to a PVDF mem-
brane on a semi-dry transfer cell for 2 hrs under constant
voltage (25 V). After transfer, the membrane was blocked
with 5% milk in 1X TBST for 30 min (250 rpm at 37°C)
and washed three times with 1X TBST. Membranes were
incubated overnight at 4°C with serum from SUB2- or
KLH- immunized mice at a 1:500 dilution in 1X TBST or
with a mouse anti-MBP antibody (Upstate–Millipore, #05-
912) at a 1:10,000 dilution in 1X TBST. After three washes
with 1X TBST, membranes were incubated with an alkaline
phosphatase-conjugated goat anti-mouse antibody (1:5,000
dilution in 1X TBST). Detection was carried out using
NBT/BCIP alkaline phosphatase substrates (Promega,
Madison, WI).
Plasmodium challenge in SUB2 immunized mice
Following immunization with either the CFA or IFA
protocols described above, SUB2 or control KLH mice
were infected with ~2×102 P. berghei mCherry [18] asex-
ual parasites via intravenous (iv) injection as previously
performed [19]. To monitor parasite growth, thin smears
of tail blood were stained with Giemsa and examined
under a microscope to determine parasitaemia (% of in-
fected erythrocytes) every day for ten days. Results were
combined for KLH- and SUB2-immunized mice using
either the IFA or CFA immunization protocols and signifi-
cance was determined using linear regression analysis.
Statistical comparisons of the parasitaemia at day 10 of in-
fected mice were performed using Mann–Whitney analysis.
To determine the effects of immunization on mouse
survival following the above Plasmodium challenge, the
survival of immunized mice was monitored for 40 days
following the initial infection. Statistical differences in
the survival curves were determined using a Log-rank
(Mantel-Cox) test.
Multiple invasion analysis
Ten days after infection with P. berghei, Giemsa-stained
thin smears from SUB2 or KLH immunized mice with
measurable parasitaemia were analysed by light micros-
copy. Independent of parasitaemia, approximately 200
infected RBCs were examined per mouse to determine
the number of infected RBCs that contained one or
more parasites. The percentage of each invasion pheno-
type was calculated as the number of invasion events,
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Significance was determined using Mann–Whitney.
Passive immunization experiments
Swiss Webster mice infected with the mCherry strain of P.
berghei [18] were examined for similar levels of exflagella-
tion three days after inoculation as previously described [9].
Mice with matching infections were anesthetized and
used for blood feeding control (pre-KLH) or treatment
(pre-SUB2) groups of Anopheles gambiae mosquitoes for
15 min. The anesthetized mice were then taken off the cage
and passively immunized (iv) with KLH or SUB2 immune
sera (final concentration of 2 mg/ml) and allowed to re-
cover for 15 min. The passively immunized mice were then
fed to sibling groups of An. gambiae mosquitoes for an
additional 15 min to measure any effects on parasite devel-
opment in the mosquito.
Following feeding, mosquitoes were incubated at
19°C to promote P. berghei development. Mosquito
midguts were dissected seven days post-blood meal
(PBM), and oocysts numbers were counted using a
compound fluorescence microscope. Oocyst numbers
from two independent experiments were pooled and
analysed by Kruskal-Wallis with a Dunn’s Multiple
Comparison test to determine significance.
Results
Structural modelling of Plasmodium berghei SUB2
catalytic domain
A structure model was predicted for the catalytic do-
main of PbSUB2 by the I-TASSER server and contains a
secondary structure topology characteristic of subtilisin-
like serine proteases (Figure 1A). The amino acid resi-
dues that comprise the catalytic triad Asp 705, His 748
and Ser 911 required for catalysis are positioned at the
active site of the model (Figure 1A). Comparing the pre-
dicted model using the EBI SSM webserver, the closest
structural homologue in the protein data bank (PDB) is
the subtilase, thermitase (PDB 1twc:E) from Thermoacti-
nomyces vulgaris. With an overall root mean square de-
viation (RMSD) of 1.4 Å for 247 amino acid residues as
determined with PDBeFold [20], therefore the predicted
structural model for PbSUB2 therefore has a high confi-
dence level, resembling the overall known fold of other
subtilases.
Design of Plasmodium berghei SUB2 peptides
Using proprietary software (GenScript), highly antigenic
peptides corresponding to the PbSUB2 catalytic domain
were identified. To test these candidate 14 amino acid
peptides, the corresponding regions were mapped on a
PbSUB2 catalytic domain homology model. Two peptides
mapping to opposite flexible solvent exposed regions of
PbSUB2 were selected to increase the likelihood thatantibodies generated against these peptides would interact
with the protease on the surface of merozoites or ookinetes
during invasion (Figure 1A). Both peptides correspond to
different solvent accessible regions of the PbSUB2 catalytic
domain (Figure 1B, left).
The sequence of Peptide #1 is nearly identical (93%) to
the corresponding region of Plasmodium yoelii SUB2
(Figure 1B, right). The two sequences only differ by the
amino acid at position Leu 734 in the P. berghei se-
quence and Phe 734 in Plasmodium yoelii, suggesting a
high level of conservation between the rodent malaria
species. Less conservation exists between Peptide #1 and
the human malaria parasites (P. falciparum, Plasmodium
vivax and Plasmodium knowlesi), with only 64% similar-
ity (36% ID) to P. falciparum (Figure 1B). However, the
Peptide #2 sequence alignment reveals more conserva-
tion and sequence similarity across Plasmodium species.
The P. berghei and P. falciparum SUB2 sequences show
85% similarity (71% ID), while the rodent malaria para-
sites are completely conserved (Figure 1B). Both peptide
sequences map to regions of the PbSUB2 catalytic do-
main (Figure 1A).
Mice immunized with SUB2 peptides recognize
recombinant PbSUB2
MBP-SUB2 expression constructs containing a short re-
gion of the pro-domain and the entirety of the SUB2
catalytic domain (Figure 2A) were expressed using a
Rosetta2 E. coli heterologous system. Recombinant
SUB2 was visualized as a single band for PbSUB2, or as
two bands for PfSUB2, of approximately 110 kDa full-
length protein products (Figure 2B). Smaller protein
products are likely the result of either sample degrad-
ation during the purification process or translational
truncation products that were observed for both SUB2
constructs (Figure 2B). The truncation products can be
explained by the occurrence of numerous rare-codons
within the SUB2 gene, leading to premature termination
during translation. Both full-length and truncated forms of
SUB2 were detected using an MBP antibody, confirming
the detection of the recombinant MBP-SUB2 fusion protein
products (Figure 2B). When incubated with immune sera
from SUB2-immunized mice, recombinant PbSUB2 is de-
tected in full length and degraded forms while only a faint
band corresponding to full-length recombinant PfSUB2
protein was detected (Figure 2B). Importantly, mice immu-
nized with KLH alone did not recognize either recombinant
SUB2 protein (Figure 2B).
These results confirm that antibodies were generated in
mice immunized with PbSUB2 peptides that can sufficiently
recognize recombinant PbSUB2 (Figure 2B). Furthermore,
immune sera raised against PbSUB2 peptides specifically
targets PbSUB2 with minimal cross-reactivity to P. falcip-
arum SUB2 (Figure 2B), suggesting that the observed
Figure 1 PbSUB2 homology models identify peptide targets for immunization. (A) Cartoon (left) or surface representation (right) homology
model of the PbSUB2 catalytic domain (residues L672-L971) visualized with PyMOL software. Regions corresponding to Peptide #1 (purple) and
Peptide #2 (green) were used for immunization experiments. Catalytic residues Asp705, His748 and S911 in the active site pocket are shown as
orange, cyan and red spheres, respectively. (B) Lateral view of Peptide #1 (purple) and Peptide #2 (green) in the PbSUB2 surface representation
model reveals that each peptide corresponds to solvent exposed areas (left). Sequence alignments of both peptide sequences with corresponding regions
of P. falciparum, P. vivax, P. knowlesi, and P. yoelii SUB2 (right). The amino acid position of the first and last residues of each peptide sequence with respect
to full length PbSUB2 are shown at the top left and right corner of each alignment. Conserved residues are highlighted with a red background and regions
of similarity are marked with red letters against white background. Sequence alignments were visualized using ESPript [21].
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cross-species protection. However, future immunization
experiments are needed to determine the properties of
the individual peptides and whether they are capable of
cross-species immune recognition of different Plasmodium
species.
SUB2-immunization impairs asexual Plasmodium
development
To monitor the effects of immunization on parasite de-
velopment, KLH- and SUB2-immunized (IFA or CFA)mice were challenged with ~2×102 P. berghei parasites
by intravenous injection and the parasitaemia was moni-
tored over the period of ten days. Blood stage infections
were detected in 17 of 18 mice, and little variation was
seen between mice immunized with the IFA or CFA
immunization protocols (Table 1). As a result, both
immunization experiments were pooled for analysis and
are summarized in Table 1. Compared to control KLH-
immunized mice, SUB2-immunized mice showed a
slight, but not significant delay in the pre-patency of in-
fection (Table 1). However, when the parasitaemia was
Figure 2 Production of recombinant SUB2 and recognition using Sub2 immune sera. (A) Domains of endogenous PbSUB2 (top): signal
peptide (residues 1–20), pro-domain (residues 21–626), catalytic domain (residues 627–1,088) with catalytic residues Asp (orange), His (cyan) and
Ser (red), transmembrane domain (residues 1,089–1,111) and cytoplasmic tail (residues 1,112–1,230). Representation of recombinant PbSUB2
(middle) containing a minimal inhibitory domain and the full catalytic domain. Below, PbSUB2 Peptides #1 (purple) and #2 (green) are
aligned to endogenous PbSUB2 and rPbSUB2 with peptide sequences. Illustrations were prepared with DOG1.0 [22]. (B) Recombinant
proteins maltose binding protein (MBP), PbSUB2 or PfSUB2 MBP-fusion proteins were separated on polyacrylamide gels and stained with
Coomassie, or transferred and visualized by Western Blot with specific MBP, SUB2, or KLH antibodies. Arrows denote full length PbSUB2
and PfSUB2 recombinant products. Approximate sizes in kilodaltons (kDa) are displayed on the left.
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asexual growth was significantly reduced and in some
mice completely attenuated following SUB2-immunization
(Figure 3A).
In SUB2-immunized mice, parasite growth was re-
duced by 37, 43, and 56% from days 8–10, effectively re-
ducing parasitaemia more than two-fold when compared
to KLH control mice (Figure 3A). In addition, nearly half
of the SUB2-immunized mice (four of nine) had cleared
all signs of parasite infection by day 10 (Figure 3B and
Table 1). None of the KLH-immunized mice infectedTable 1 Summary of immunization experiments
Experiment Adjuvant Antigen # Mice Inf
1 IFA KLH 6 5/6
SUB2 6 6/6
2 CFA KLH 3 3/3
SUB2 3 3/3
Total KLH 9 8/9
SUB2 9 9/9
*Mice with detected parasitemia that had cleared the parasite infection (measured
§Average number of days mice survived following P. berghei challenge.with P. berghei was able to clear the infection over the
duration of the experiment (Figure 3B and Table 1).SUB2-immunization increases mouse survival after
Plasmodium berghei challenge
Since P. berghei asexual development is reduced in
SUB2-immunized mice (Figure 3A), the possibility that
SUB2-immunization also protects mice against malaria
lethality through the decreased parasite burden was








Figure 3 SUB2 immunization reduces the intensity of Plasmodium berghei infection and increases mouse survival. The parasitaemia of
KLH- or SUB2-immunized mice was determined over the period of ten days after infection with P. berghei parasites (A). Each point represents the
mean parasitaemia (n = 9) with error bars displaying standard errors of the mean and the asterisk denoting significance (P = 0.0042). The scatter
plot displays the parasitaemia at day 10, with each point representing the parasitaemia of individual KLH- or SUB2-immunized mice (B). The red
bar represents the median of each experiment with the asterisk denoting significance (P < 0.05). The survival of KLH- and SUB2-immunized
mice was monitored over the course of forty days following P. berghei challenge (C). The number of surviving mice for each treatment over
the duration of the experiment is displayed as a percentage of the total number of infected mice at a given time point. Statistical differences
are marked by an asterisk (P = 0.0082).
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the same KLH- and SUB2-immunized mice were moni-
tored for a total of 40 days to examine survival following
P. berghei challenge (Figure 3C). In these experiments,
SUB2-immunized mice showed increased survival over
control KLH-immunized mice (Figure 3C and Table 1).
On average, SUB2-immunized mice survived for more
than one week longer than KLH control mice (Table 1),
and seven of nine mice survived the duration of the ex-
periment (Figure 3C). In contrast, only one of the eight
infected KLH mice survived the entire 40-day period
(Figure 3C). This would suggest that the attenuated
malaria parasite growth seen in SUB2-immunized mice
(Figure 3A) also translates to an increased survival fol-
lowing P. berghei challenge (Figure 3C).
SUB2-immunization promotes aberrant red blood cell
invasion
Based upon observations measuring the parasitaemia of
the immunized mice (Figure 3A), there appeared to be aFigure 4 SUB2-immunization promotes multiple invasion of red bloo
(3+) events in P. berghei-infected red blood cells are depicted with their co
mice at ten days post-infection. The percentage of each invasion phenotyp
significant differences between KLH-and SUB2-immunized mice (P < 0.01).noticeable increase in the number of infected RBCs with
multiple parasites in SUB2-immunized mice. To quantify
these presumed defects in invasion, the percentages of
infected RBCs that had one, two, or multiple (three+)
parasites were measured in KLH- and SUB2-immunized
mice (Figure 4). Validating previous observations, SUB2-
immunized mice had a significant decrease in the number
of infected RBCs that had undergone a single invasion
event when compared to KLH-control mice (Figure 4).
In turn, corresponding increases in the number of
double or multiple invasion events (three+) following
SUB2 immunization were also detected (Figure 4).
Based upon these data and the important functional role
of SUB2 in RBC invasion [12,15], it is clear that SUB2-
immunization interferes with merozoite invasion. Although
it is not completely understood how SUB2-immunization
might influence the production of these aberrant invasion
events, previous studies using antibodies to merozoite
surface proteins similarly report phenotypes promoting
multiple invasion [23,24].d cells. Representative images of single, double, or multiple invasion
rresponding percentages in KLH- (black) or SUB2- (grey) immunized
e is displayed as the mean and standard error. Asterisks denote
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invasion in passively immunized mice
One previous study has reported that SUB2 is expressed
by ookinetes, implicating that SUB2 may be secreted
into the cytoplasm of ookinete-invaded cells as the para-
site traverses the midgut epithelium [10]. Immunofluor-
escence staining identified SUB2 protein aggregates in
close proximity to the actin cytoskeleton, which suggests
SUB2 may play an important role in cytoskeleton modi-
fications during the process of ookinete invasion [14].
To address the role of SUB2 in ookinete midgut invasion
and the potential role that SUB2 immune sera could also
inhibit ookinete invasion, passive immunization assays were
performed to determine the effects on parasite develop-
ment in the mosquito. As expected, passive immunization
with the control KLH immune sera did not significantly
alter Plasmodium oocyst numbers (Figure 5). Similarly, pas-
sive immunization with SUB2 immune sera did not signifi-
cantly alter oocyst numbers (Figure 5), suggesting that
SUB2 may either not be required for ookinete invasion of
the mosquito midgut or that the immune sera was present
in suboptimal levels needed to inhibit ookinete invasion.
These research questions highlight the need for further in-
vestigation into the role of SUB2 during the mosquito
stages of Plasmodium development.
Discussion
Although more than 40% of the world’s population is at
risk of malaria transmission, only limited resources existFigure 5 Passive immunization with SUB2 immune sera does
not influence parasite growth in the mosquito. Oocyst numbers
were measured to determine the effects of passive immunization to
control KLH- or SUB2-immune sera. Plasmodium berghei-infected
mice were fed to mosquitoes and oocyst numbers were determined
for each experimental group before passive immunization (pre-KLH
or pre-SUB2), or following passive immunization (KLH or SUB2). The
total number (n) of mosquito midguts examined is displayed under
each experimental group. The red bar denotes the median of each
experiment. No significant (ns) differences were identified for either
experimental group following passive immunization.to readily combat Plasmodium parasites. Current drug
therapy faces the ever-increasing risk of resistance [25] and
while multiple approaches have thus far been employed to
create a malaria vaccine, they have had only mixed results
in clinical trials [26]. As a result, new strategies to reduce
malaria transmission are desperately needed.
Plasmodium species utilize many different proteases
during their complex life cycle in the human and mos-
quito hosts, and serve as optimal targets to interfere
with malaria transmission. Previous reports have demon-
strated the required role of a Plasmodium subtilase
(SUB2) for asexual development through its role as a
sheddase required for merozoite invasion [12,15]. Add-
itional studies have also implicated SUB2 in ookinete in-
vasion [14], thus making SUB2 an attractive target to
interfere with parasite development in both its human
and mosquito hosts.
Using a rodent model, the potential of targeting SUB2
by immunizing mice against specific SUB2-derived
peptides was addressed. When compared to control
KLH-immunized mice, SUB2-immunization resulted in
a slight delay in prepatency, decreased parasitaemia
when monitored over a ten-day period, and increased
survival following infection. Similar results were ob-
tained independent of the method of immunization,
suggesting that the effects of immunization are primar-
ily that of the SUB2 antigens and not from non-specific
effects mediated by the CFA. Together, these data would
suggest that SUB2-immunization greatly impairs para-
site growth, likely by interfering with the efficacy of
merozoite invasion.
In support of this idea, an increase in the number of
multiple-invaded RBCs following SUB2-immunization
was detected, suggesting that merozoite invasion is sig-
nificantly altered. Similar effects have been seen in other
studies using antibodies targeting merozoite proteins,
where it was proposed that multiple invasions are the
result of merozoite agglutination [23,24]. According to
this hypothesis, the invasion of some merozoites may
be completely blocked, while incomplete inhibition
may result in multiple parasites that have been cross-
linked by SUB2 antibodies that undergo invasion to-
gether as a complex or dissociate once the RBC surface
has been recognized. Alternatively, if RBC invasion is
slowed in the presence of SUB2 antibodies, multiple
merozoites may invade the same cell before the para-
site can direct modifications to the RBC surface to
prevent further invasion. Due to the short time frame
in which merozoites undergo release and invasion into
new RBCs, the concentration and rate of antibody
binding may be critical factors in invasion inhibition.
Very little information exists regarding the viability
of infected RBCs that have undergone multiple inva-
sion events. It has been hypothesized that nutritional
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http://www.malariajournal.com/content/13/1/313and structural limitations following multiple invasion
may reduce the production of viable merozoites [24],
thus raising the possibility that these infected RBCs
may be a ‘dead-end’ for the parasite. As a result, the
higher incidence of multiple invasions may have a sig-
nificant contribution to the decreased parasitaemia
and increased survival in the SUB2-immunized mice.
While the increased survival of SUB2-immunized
mice would suggest that SUB2 immunization can con-
fer protection to the severe forms of malaria infection,
the potential reasons for morbidity in the Plasmo-
dium-infected mice was not further explored. Visible
neurological symptoms of cerebral malaria (as defined
by [27]) were not observed, suggesting that infection-
induced mortality was due to other malaria-related
causes.
Based upon previous studies implicating SUB2 in
ookinete invasion [14], the role of SUB2 on parasite
development in the mosquito was examined using pas-
sive immunization assays. Although differences in oo-
cyst development were not detected, it still remains
unclear what role SUB2 may have during the process
of ookinete invasion. Given the limited amount of
immune sera produced, only one concentration was
tested in the passive immunization experiments and
these may have been suboptimal concentrations to in-
hibit ookinete invasion. Alternatively, the production
of SUB2 by ookinetes may not be integral to ookinete
motility within the mosquito midgut and may not be a
viable target to interfere with malaria transmission. As
a result, the role of SUB2 in Plasmodium ookinetes
requires future study.Conclusion
These experiments indicate that immunization against
a merozoite sheddase can interfere with Plasmodium
development in mice. While the results are still prelim-
inary using a rodent malaria model, the data provide
strong evidence for future investigation into the use of
SUB2 as a vaccine or drug target to interrupt parasite
development in more relevant human malaria models.
In support of this idea, epidemiological studies in
Papua New Guinea indicate a strong correlation be-
tween the detection of SUB2 antibodies and naturally
acquired protective immunity [7]. Similar studies with
blood samples from field isolates of African popula-
tions to determine the role of SUB2 in naturally
acquired immunity could provide further verification
for this promising approach as a vaccine candidate. As
a result, future experiments will address challenges to
increase the efficacy to inhibit SUB2 function using
monoclonal antibodies or small molecules inhibitors to
interrupt merozoite invasion.Additional file
Additional file 1: Parasitaemia of individual immunized mice
following Plasmodium berghei challenge.
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